K-252b

• UNSPSC Description:

  K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through cell membrane freely [1][2][3].

• Target Antigen:

  PKC

• Type:

  Natural Products

• Related Pathways:

  Epigenetics;TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/k-252b.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@]([C@@]1(O)C(O)=O)(O[C@](N2C3=CC=CC=C43)([H])C1)N5C(C2=C4C6=C7CNC6=O)=C7C8=CC=CC=C58

• Molecular Weight:

  453.45

• References & Citations:

  [1]Yasuzawa, T., et al. The structures of the novel protein kinase C inhibitors K-252a, b, c AND d Journal of Antibiotics 39(8), 1072-1078 (1986).|[2]Plomp, J.J., et al. Involvement of protein kinases in the upregulation of acetylcholine release at endplates of α-bungarotoxin-treated rats Journal of Physiology 493, 175-186 (1996).|[3]Zhu, X., et al. Evidence of ectokinase-mediated phosphorylation of osteopontin and bone sialoprotein by osteoblasts during bone formation in vitro Biochemistry Journal 323, 637-643 (1997).

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  99570-78-2